1
|
Stenger F, Seidel P, Schricker T, Volc S, Fischer J. Could cat flea bites contribute to alpha-gal serum IgE levels in humans? J Investig Allergol Clin Immunol 2022; 32:494-495. [DOI: 10.18176/jiaci.0784] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
2
|
Abrahao-Machado LF, Pinto F, Antunes B, Volc S, Boldrini E, Camargo OPD, Reis RM. Clinical impact of brachyury expression in Ewing sarcoma patients. Adv Med Sci 2021; 66:321-325. [PMID: 34273746 DOI: 10.1016/j.advms.2021.06.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2020] [Revised: 05/21/2021] [Accepted: 06/25/2021] [Indexed: 10/20/2022]
Abstract
PURPOSE The T-box transcription factor brachyury has been demonstrated as a prognostic factor in a variety of cancer types and considered a novel oncotarget in solid tumors. Brachyury acts as a regulator of the epithelial-mesenchymal transition (EMT) process, leading to more aggressive behavior and poorer prognosis. However, recent literature evidence suggests a tumor suppressor role in other neoplasms. In the present study, we aimed to study brachyury expression and its prognostic impact in Ewing sarcoma, an aggressive neoplasm of young individuals. METHODS We analyzed the expression of brachyury by immunohistochemistry in a series of 96 Ewing sarcomas in a tissue microarray and investigated the association of the protein expression with the clinical parameters and overall survival. RESULTS More than half of the cases (51%, n = 49) depicted positive nuclear brachyury expression, while a lack of expression was observed in 49% (n = 47) of cases. Nuclear brachyury staining was significantly associated with non-white ethnicity (p = 0.04) and axial localization (p = 0.025). Importantly, lack of brachyury expression was significantly associated with lower overall survival in multivariate analyses (hazard ratio - HR: 2.227, p = 0.008). CONCLUSIONS Our findings indicate, that brachyury is an independent prognostic biomarker in Ewing sarcoma, which might suggest a tumor suppressor role and which yet to be fully elucidated.
Collapse
|
3
|
Affiliation(s)
- J Berger
- Department of Dermatology, Eberhard-Karls-University Tuebingen, Tuebingen, Germany
| | - S Volc
- Department of Dermatology, Eberhard-Karls-University Tuebingen, Tuebingen, Germany
| |
Collapse
|
4
|
Pinto EM, Figueiredo BC, Chen W, Galvao HC, Formiga MN, Fragoso MCB, Ashton-Prolla P, Ribeiro EM, Felix G, Costa TE, Savage SA, Yeager M, Palmero EI, Volc S, Salvador H, Fuster-Soler JL, Lavarino C, Chantada G, Vaur D, Odone-Filho V, Brugières L, Else T, Stoffel EM, Maxwell KN, Achatz MI, Kowalski L, de Andrade KC, Pappo A, Letouze E, Latronico AC, Mendonca BB, Almeida MQ, Brondani VB, Bittar CM, Soares EW, Mathias C, Ramos CR, Machado M, Zhou W, Jones K, Vogt A, Klincha PP, Santiago KM, Komechen H, Paraizo MM, Parise IZ, Hamilton KV, Wang J, Rampersaud E, Clay MR, Murphy AJ, Lalli E, Nichols KE, Ribeiro RC, Rodriguez-Galindo C, Korbonits M, Zhang J, Thomas MG, Connelly JP, Pruett-Miller S, Diekmann Y, Neale G, Wu G, Zambetti GP. XAF1 as a modifier of p53 function and cancer susceptibility. Sci Adv 2020; 6:eaba3231. [PMID: 32637605 PMCID: PMC7314530 DOI: 10.1126/sciadv.aba3231] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/26/2019] [Accepted: 05/14/2020] [Indexed: 05/15/2023]
Abstract
Cancer risk is highly variable in carriers of the common TP53-R337H founder allele, possibly due to the influence of modifier genes. Whole-genome sequencing identified a variant in the tumor suppressor XAF1 (E134*/Glu134Ter/rs146752602) in a subset of R337H carriers. Haplotype-defining variants were verified in 203 patients with cancer, 582 relatives, and 42,438 newborns. The compound mutant haplotype was enriched in patients with cancer, conferring risk for sarcoma (P = 0.003) and subsequent malignancies (P = 0.006). Functional analyses demonstrated that wild-type XAF1 enhances transactivation of wild-type and hypomorphic TP53 variants, whereas XAF1-E134* is markedly attenuated in this activity. We propose that cosegregation of XAF1-E134* and TP53-R337H mutations leads to a more aggressive cancer phenotype than TP53-R337H alone, with implications for genetic counseling and clinical management of hypomorphic TP53 mutant carriers.
Collapse
Affiliation(s)
- Emilia M. Pinto
- Department of Pathology, St. Jude Children’s Research Hospital, Memphis, TN, USA
- Corresponding author. (E.M.P.); (G.P.Z.)
| | | | - Wenan Chen
- Center for Applied Bioinformatics, St. Jude Children’s Research Hospital, Memphis, TN, USA
| | | | | | | | | | | | | | | | | | | | | | - Sahlua Volc
- Hospital de Cancer de Barretos, Barretos, SP, Brazil
| | - Hector Salvador
- Pediatric Oncology Department, Sant Joan de Deu Hospital, Barcelona, Spain
| | | | - Cinzia Lavarino
- Pediatric Oncology Department, Sant Joan de Deu Hospital, Barcelona, Spain
| | - Guillermo Chantada
- Department of Global Pediatric Medicine, St. Jude Children’s Research Hospital, Memphis, TN, USA
| | - Dominique Vaur
- Comprehensive Cancer Center François Baclesse, Caen, France
| | - Vicente Odone-Filho
- ITACI–Instituto de Tratamento do Câncer Infantil do Departamento de Pediatria da Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, SP, Brazil
| | | | | | | | - Kara N. Maxwell
- Perelman School of Medicine University of Pennsylvania, Philadelphia, PA, USA
| | | | | | | | - Alberto Pappo
- Department of Oncology, St. Jude Children’s Research Hospital, Memphis, TN, USA
| | - Eric Letouze
- Centre de Recherche des Cordeliers, Paris, France
| | | | | | | | | | - Camila M. Bittar
- Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil
| | | | | | | | | | - Weiyin Zhou
- National Cancer Institute, Rockville, MD, USA
| | | | | | | | | | - Heloisa Komechen
- Instituto de Pesquisa Pelé Pequeno Principe, Curitiba, PR, Brazil
| | | | - Ivy Z.S. Parise
- Instituto de Pesquisa Pelé Pequeno Principe, Curitiba, PR, Brazil
| | - Kayla V. Hamilton
- Department of Oncology, St. Jude Children’s Research Hospital, Memphis, TN, USA
| | - Jinling Wang
- Department of Pathology, St. Jude Children’s Research Hospital, Memphis, TN, USA
| | - Evadnie Rampersaud
- Center for Applied Bioinformatics, St. Jude Children’s Research Hospital, Memphis, TN, USA
| | - Michael R. Clay
- Department of Pathology, St. Jude Children’s Research Hospital, Memphis, TN, USA
| | - Andrew J. Murphy
- Department of Surgery, St. Jude Children’s Research Hospital, Memphis, TN, USA
| | - Enzo Lalli
- Institut de Pharmacologie Moléculaire et Cellulaire, Valbonne, France
| | - Kim E. Nichols
- Department of Oncology, St. Jude Children’s Research Hospital, Memphis, TN, USA
| | - Raul C. Ribeiro
- Department of Oncology, St. Jude Children’s Research Hospital, Memphis, TN, USA
| | - Carlos Rodriguez-Galindo
- Department of Global Pediatric Medicine, St. Jude Children’s Research Hospital, Memphis, TN, USA
| | - Marta Korbonits
- Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
| | - Jinghui Zhang
- Center for Applied Bioinformatics, St. Jude Children’s Research Hospital, Memphis, TN, USA
| | - Mark G. Thomas
- Research Department of Genetics, Evolution and Environment, University College London, London, UK
| | - Jon P. Connelly
- Center for Advanced Genome Engineering, St. Jude Children’s Research Hospital, Memphis, TN, USA
| | - Shondra Pruett-Miller
- Center for Advanced Genome Engineering, St. Jude Children’s Research Hospital, Memphis, TN, USA
| | - Yoan Diekmann
- Research Department of Genetics, Evolution and Environment, University College London, London, UK
| | - Geoffrey Neale
- Hartwell Center for Bioinformatics and Biotechnology, St. Jude Children's Research Hospital, Memphis, TN, USA
| | - Gang Wu
- Center for Applied Bioinformatics, St. Jude Children’s Research Hospital, Memphis, TN, USA
| | - Gerard P. Zambetti
- Department of Pathology, St. Jude Children’s Research Hospital, Memphis, TN, USA
- Corresponding author. (E.M.P.); (G.P.Z.)
| |
Collapse
|
5
|
Volc S, Maier L, Gritsch A, Aichelburg MC, Volc-Platzer B. Successful treatment of Netherton syndrome with ustekinumab in a 15-year-old girl. Br J Dermatol 2020; 183:165-167. [PMID: 31977080 DOI: 10.1111/bjd.18892] [Citation(s) in RCA: 31] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- S Volc
- Department of Dermatology, Eberhard-Karls-University Tübingen, Tübingen, Germany
| | - L Maier
- Department of Dermatology, Donauspital Vienna, Vienna, Austria.,Karl Landsteiner Institute for Paediatric Dermatology, Vienna, Austria
| | - A Gritsch
- Department of Dermatology, Donauspital Vienna, Vienna, Austria
| | - M C Aichelburg
- Department of Dermatology, Donauspital Vienna, Vienna, Austria
| | - B Volc-Platzer
- Department of Dermatology, Donauspital Vienna, Vienna, Austria.,Karl Landsteiner Institute for Paediatric Dermatology, Vienna, Austria
| |
Collapse
|
6
|
Volc S, Maier JCP, Breuninger H, Hund V, Häfner HM, Kofler L. Manufacture and use of tumescence solution meeting hospital-required hygiene conditions - practical implications. J Eur Acad Dermatol Venereol 2019; 33:e434-e435. [PMID: 31220369 DOI: 10.1111/jdv.15754] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2019] [Revised: 05/15/2019] [Accepted: 06/06/2019] [Indexed: 12/28/2022]
Affiliation(s)
- S Volc
- Department of Dermatology, Eberhard-Karls University Tübingen, Tübingen, Germany
| | - J C P Maier
- Department of Dermatology, Eberhard-Karls University Tübingen, Tübingen, Germany
| | - H Breuninger
- Department of Dermatology, Eberhard-Karls University Tübingen, Tübingen, Germany
| | - V Hund
- University Pharmacy, Eberhard-Karls University Tübingen, Tübingen, Germany
| | - H-M Häfner
- Department of Dermatology, Eberhard-Karls University Tübingen, Tübingen, Germany
| | - L Kofler
- Department of Dermatology, Eberhard-Karls University Tübingen, Tübingen, Germany
| |
Collapse
|
7
|
Fernandes GC, Michelli RAD, Galvão HCR, Paula AE, Pereira R, Andrade CE, Felicio PS, Souza CP, Mendes DRP, Volc S, Berardinelli GN, Grasel RS, Sabato CS, Viana DV, Mauad EC, Scapulatempo-Neto C, Arun B, Reis RM, Palmero EI. Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry. Oncotarget 2018; 7:80465-80481. [PMID: 27741520 PMCID: PMC5348334 DOI: 10.18632/oncotarget.12610] [Citation(s) in RCA: 51] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2016] [Accepted: 10/01/2016] [Indexed: 11/25/2022] Open
Abstract
Background There are very few data about the mutational profile of families at-risk for hereditary breast and ovarian cancer (HBOC) from Latin America (LA) and especially from Brazil, the largest and most populated country in LA. Results Of the 349 probands analyzed, 21.5% were BRCA1/BRCA2 mutated, 65.3% at BRCA1 and 34.7% at BRCA2 gene. The mutation c.5266dupC (former 5382insC) was the most frequent alteration, representing 36.7% of the BRCA1 mutations and 24.0% of all mutations identified. Together with the BRCA1 c.3331_3334delCAAG mutation, these mutations constitutes about 35% of the identified mutations and more than 50% of the BRCA1 pathogenic mutations. Interestingly, six new mutations were identified. Additionally, 39 out of the 44 pathogenic mutations identified were not previously reported in the Brazilian population. Besides, 36 different variants of unknown significance (VUS) were identified. Regarding ancestry, average ancestry proportions were 70.6% European, 14.5% African, 8.0% Native American and 6.8% East Asian. Materials and methods This study characterized 349 Brazilian families at-risk for HBOC regarding their germline BRCA1/BRCA2 status and genetic ancestry. Conclusions This is the largest report of BRCA1/BRCA2 assessment in an at-risk HBOC Brazilian population. We identified 21.5% of patients harboring BRCA1/BRCA2 mutations and characterized the genetic ancestry of a sample group at-risk for hereditary breast cancer showing once again how admixed is the Brazilian population. No association was found between genetic ancestry and mutational status. The knowledge of the mutational profile in a population can contribute to the definition of more cost-effective strategies for the identification of HBOC families.
Collapse
Affiliation(s)
- Gabriela C Fernandes
- Center of Molecular Diagnosis, Barretos Cancer Hospital, Barretos, São Paulo, Brazil
| | | | - Henrique C R Galvão
- Oncogenetics Department, Barretos Cancer Hospital, Barretos, São Paulo, Brazil
| | - André E Paula
- Center of Molecular Diagnosis, Barretos Cancer Hospital, Barretos, São Paulo, Brazil
| | - Rui Pereira
- Institute of Research and Innovation in Health, University of Porto, Porto, Portugal.,Institute of Molecular Pathology and Immunology at the University of Porto (IPATIMUP), Porto, Portugal
| | - Carlos E Andrade
- Oncogenetics Department, Barretos Cancer Hospital, Barretos, São Paulo, Brazil
| | - Paula S Felicio
- Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil
| | - Cristiano P Souza
- Oncogenetics Department, Barretos Cancer Hospital, Barretos, São Paulo, Brazil
| | - Deise R P Mendes
- Center of Molecular Diagnosis, Barretos Cancer Hospital, Barretos, São Paulo, Brazil
| | - Sahlua Volc
- Oncogenetics Department, Barretos Cancer Hospital, Barretos, São Paulo, Brazil
| | | | - Rebeca S Grasel
- Oncogenetics Department, Barretos Cancer Hospital, Barretos, São Paulo, Brazil
| | - Cristina S Sabato
- Center of Molecular Diagnosis, Barretos Cancer Hospital, Barretos, São Paulo, Brazil
| | - Danilo V Viana
- Oncogenetics Department, Barretos Cancer Hospital, Barretos, São Paulo, Brazil
| | - Edmundo C Mauad
- Oncogenetics Department, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.,Prevention Department, Barretos Cancer Hospital, Barretos, São Paulo, Brazil
| | - Cristovam Scapulatempo-Neto
- Center of Molecular Diagnosis, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.,Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.,Pathology Department, Barretos Cancer Hospital, Barretos, São Paulo, Brazil
| | - Banu Arun
- MD Anderson Cancer Center, Houston, Texas, USA
| | - Rui M Reis
- Center of Molecular Diagnosis, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.,Oncogenetics Department, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.,Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.,Life and Health Sciences Research Institute (ICVS), Health Sciences School, University of Minho, Braga, Portugal.,ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal
| | - Edenir I Palmero
- Center of Molecular Diagnosis, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.,Oncogenetics Department, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.,Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.,Barretos School of Health Sciences, Dr. Paulo Prata-FACISB, São Paulo, Brazil
| |
Collapse
|
8
|
Abrahao-Machado LF, Antunes B, Filippi RZ, Volc S, Boldrini E, Menezes WP, Reis RM, de Camargo OP. Loss of MTAP expression is a negative prognostic marker in Ewing sarcoma family of tumors. Biomark Med 2018; 12:35-44. [DOI: 10.2217/bmm-2017-0152] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Aim: The Ewing sarcoma family of tumors (ESFT) is a group of malignant small round cell neoplasms of bones and soft tissues closely histogenetically related. Methylthioadenosine phosphorylase (MTAP) deficiency has been recently associated with increased tumor aggressiveness and poor outcomes in different types of neoplasms. However, the expression of this biomarker and its biological role in ESFT remain largely unknown. Methods: Immunohistochemical expression of MTAP was accessed in 112 patients with ESFT in a tissue microarray platform and associated with clinicopathological parameters and overall survival (OS). Results: Loss of MTAP expression was significantly associated with lower OS in both univariate and multivariate analyses. Conclusion: Loss of MTAP expression is an independent negative prognostic biomarker in ESFT.
Collapse
Affiliation(s)
| | - Bruno Antunes
- Department of Othopedics Surgery, Barretos Cancer Hospital, Barretos, SP, Brazil
| | - Renee Zon Filippi
- Institute of Orthopedics & Traumatology, Faculty of Medicine, University of São Paulo (FMUSP), São Paulo, SP, Brazil
| | - Sahlua Volc
- Oncology Department, Barretos Cancer Hospital, Barretos, SP, Brazil
| | - Erica Boldrini
- Pediatrics Department, Barretos Cancer Hospital, Barretos, SP, Brazil
| | - Weder P Menezes
- Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, SP, Brazil
| | - Rui M Reis
- Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, SP, Brazil
- Life & Health Sciences Research Institute (ICVS), Health Sciences School, University of Minho, Braga, Portugal
- ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal
| | - Olavo Pires de Camargo
- Institute of Orthopedics & Traumatology, Faculty of Medicine, University of São Paulo (FMUSP), São Paulo, SP, Brazil
| |
Collapse
|
9
|
Volc S, Maier JC, Röcken M. [Skin diseases due to systemic vasculitides and vasculopathies]. Hautarzt 2017; 67:948-959. [PMID: 27864582 DOI: 10.1007/s00105-016-3896-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Vasculitis and vasculopathy are two distinct disease entities. Each entity comprises a large number of heterogeneous diseases, which can occur alone or associated with autoimmune, infectious or neoplastic diseases. The terms vasculitis and vasculopathy are often falsely used synonymously. A vasculitis initially causes inflammation of the vessel walls that may result in a secondary occlusion. In contrast, a vasculopathy is a primary occlusion of the vascular lumen, which is followed by inflammation after ischemia and ulceration. In most patients the distinction can be made based on the clinical presentation. A clear clinical diagnosis is then followed by targeted serological, histological and imaging procedures to confirm the clinical diagnosis. On this basis a well-founded treatment can be initiated. In the presence of vasculitis an anti-inflammatory therapy is indicated, whereas in the case of vasculopathy, removal of the vascular occlusion is the main focus. This article provides an overview of the various diseases and addresses the pathogenetic and clinical characteristics used to differentiate the individual disease entities. It also provides an insight into the therapy options and prophylaxis.
Collapse
Affiliation(s)
- S Volc
- Universitäts-Hautklinik Tübingen, Liebermeisterstr. 25, 72076, Tübingen, Deutschland
| | - J C Maier
- Universitäts-Hautklinik Tübingen, Liebermeisterstr. 25, 72076, Tübingen, Deutschland
| | - M Röcken
- Universitäts-Hautklinik Tübingen, Liebermeisterstr. 25, 72076, Tübingen, Deutschland.
| |
Collapse
|
10
|
Volc S, Ghoreschi K. Reporting the response to anti-tumour necrosis factor treatment. Br J Dermatol 2016; 175:867-868. [DOI: 10.1111/bjd.14988] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- S. Volc
- Department of Dermatology; University Medical Centre, Eberhard Karls University Tübingen; Liebermeisterstrasse 25 D-72076 Tübingen Germany
| | - K. Ghoreschi
- Department of Dermatology; University Medical Centre, Eberhard Karls University Tübingen; Liebermeisterstrasse 25 D-72076 Tübingen Germany
| |
Collapse
|
11
|
Palmero EI, Galvão HCR, Fernandes GC, Paula AED, Oliveira JC, Souza CP, Andrade CE, Romagnolo LGC, Volc S, C Neto M, Sabato C, Grasel R, Mauad E, Reis RM, Michelli RAD. Oncogenetics service and the Brazilian public health system: the experience of a reference Cancer Hospital. Genet Mol Biol 2016; 39:168-77. [PMID: 27192127 PMCID: PMC4910553 DOI: 10.1590/1678-4685-gmb-2014-0364] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2014] [Accepted: 07/21/2015] [Indexed: 11/22/2022] Open
Abstract
The identification of families at-risk for hereditary cancer is extremely important
due to the prevention potential in those families. However, the number of Brazilian
genetic services providing oncogenetic care is extremely low for the continental
dimension of the country and its population. Therefore, at-risk patients do not
receive appropriate assistance. This report describes the creation, structure and
management of a cancer genetics service in a reference center for cancer prevention
and treatment, the Barretos Cancer Hospital (BCH). The Oncogenetics Department (OD)
of BCH offers, free of charge, to all patients/relatives with clinical criteria, the
possibility to perform i) genetic counseling, ii) preventive examinations and iii)
genetic testing with the best quality standards. The OD has a multidisciplinary team
and is integrated with all specialties. The genetic counseling process consists
(mostly) of two visits. In 2014, 614 individuals (371 families) were seen by the OD.
To date, over 800 families were referred by the OD for genetic testing. The support
provided by the Oncogenetics team is crucial to identify at-risk individuals and to
develop preventive and personalized behaviors for each situation, not only to the
upper-middle class population, but also to the people whose only possibility is the
public health system.
Collapse
Affiliation(s)
- Edenir I Palmero
- Centro de Pesquisa em Oncologia Molecular, Hospital de Câncer de Barretos, Barretos, SP, Brazil.,Faculdade de Ciências de Saúde de Barretos, Dr. Paulo Prata - FACISB, Barretos, SP, Brazil.,Departamento de Oncogenética, Hospital de Câncer de Barretos, Barretos, SP, Brazil
| | - Henrique C R Galvão
- Departamento de Oncogenética, Hospital de Câncer de Barretos, Barretos, SP, Brazil
| | - Gabriela C Fernandes
- Centro de Pesquisa em Oncologia Molecular, Hospital de Câncer de Barretos, Barretos, SP, Brazil.,Departamento de Oncogenética, Hospital de Câncer de Barretos, Barretos, SP, Brazil
| | - André E de Paula
- Centro de Pesquisa em Oncologia Molecular, Hospital de Câncer de Barretos, Barretos, SP, Brazil.,Departamento de Oncogenética, Hospital de Câncer de Barretos, Barretos, SP, Brazil
| | - Junea C Oliveira
- Departamento de Oncogenética, Hospital de Câncer de Barretos, Barretos, SP, Brazil
| | - Cristiano P Souza
- Departamento de Oncogenética, Hospital de Câncer de Barretos, Barretos, SP, Brazil
| | - Carlos E Andrade
- Departamento de Oncogenética, Hospital de Câncer de Barretos, Barretos, SP, Brazil
| | - Luis G C Romagnolo
- Departamento de Oncogenética, Hospital de Câncer de Barretos, Barretos, SP, Brazil
| | - Sahlua Volc
- Departamento de Oncogenética, Hospital de Câncer de Barretos, Barretos, SP, Brazil
| | - Maximiliano C Neto
- Departamento de Oncogenética, Hospital de Câncer de Barretos, Barretos, SP, Brazil
| | - Cristina Sabato
- Centro de Pesquisa em Oncologia Molecular, Hospital de Câncer de Barretos, Barretos, SP, Brazil.,Departamento de Oncogenética, Hospital de Câncer de Barretos, Barretos, SP, Brazil
| | - Rebeca Grasel
- Departamento de Oncogenética, Hospital de Câncer de Barretos, Barretos, SP, Brazil
| | - Edmundo Mauad
- Centro de Pesquisa em Oncologia Molecular, Hospital de Câncer de Barretos, Barretos, SP, Brazil.,Departamento de Oncogenética, Hospital de Câncer de Barretos, Barretos, SP, Brazil
| | - Rui M Reis
- Centro de Pesquisa em Oncologia Molecular, Hospital de Câncer de Barretos, Barretos, SP, Brazil.,Departamento de Oncogenética, Hospital de Câncer de Barretos, Barretos, SP, Brazil.,Life and Health Sciences Research Institute (ICVS), Health Sciences School, University of Minho, Braga, Portugal.,ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal
| | - Rodrigo A D Michelli
- Departamento de Oncogenética, Hospital de Câncer de Barretos, Barretos, SP, Brazil
| |
Collapse
|
12
|
Abstract
In clinical practice dermatologists may be faced with andrological findings raising interdisciplinary problems. Consideration of them may not only improve the clinical course of the patient but also the dermatologist's interdisciplinary standing. This overview describes and explains the most important andrological findings, which may be apparent in a dermatologic whole-body examination.
Collapse
Affiliation(s)
- S Volc
- Universitäts-Hautklinik Tübingen, Liebermeisterstraße 25, 72076, Tübingen, Deutschland.
| | - St Schanz
- Niedergelassener Dermatologe, Hautarztpraxis Hechingen, Hechingen, Deutschland
| |
Collapse
|